Ser235
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.2
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser235  -  S6 (human)

Site Information
IAKRRRLssLRAsts   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 448092
Available spectra:  3 CST
Associated spectra:  5 CST

In vivo Characterization
Methods used to characterize site in vivo:
electrophoretic mobility shift ( 941 ) , flow cytometry ( 86 ) , immunoassay ( 12 , 15 , 93 , 105 , 118 , 125 , 306 ) , immunoprecipitation ( 22 , 52 , 125 , 167 , 738 ) , mass spectrometry ( 26 , 32 , 34 , 39 , 42 , 50 , 52 , 53 , 57 , 60 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 74 , 77 , 78 , 80 , 82 , 83 , 84 , 85 , 87 , 89 , 90 , 91 , 92 , 94 , 97 , 98 , 99 , 100 , 101 , 102 , 103 , 104 , 106 , 107 , 108 , 109 , 110 , 111 , 112 , 113 , 114 , 116 , 117 , 119 , 120 , 121 , 122 , 123 , 124 , 127 , 128 , 129 , 130 , 131 , 132 , 133 , 134 , 135 , 136 , 137 , 138 , 139 , 141 , 142 , 143 , 144 , 145 , 146 , 147 , 148 , 149 , 150 , 151 , 152 , 154 , 155 , 156 , 157 , 158 , 159 , 160 , 161 , 162 , 164 , 165 , 166 , 168 , 169 , 170 , 171 , 172 , 173 , 174 , 176 , 177 , 179 , 180 , 181 , 182 , 183 , 184 , 185 , 186 , 187 , 188 , 189 , 190 , 191 , 192 , 193 , 194 , 195 , 196 , 197 , 198 , 199 , 200 , 201 , 202 , 203 , 204 , 205 , 206 , 207 , 208 , 209 , 210 , 211 , 212 , 213 , 215 , 216 , 219 , 220 , 221 , 222 , 223 , 224 , 225 , 226 , 227 , 228 , 229 , 230 , 231 , 232 , 233 , 234 , 235 , 236 , 237 , 238 , 239 , 240 , 241 , 242 , 243 , 244 , 245 , 246 , 247 , 248 , 250 , 251 , 252 , 253 , 254 , 255 , 256 , 257 , 258 , 259 , 261 , 262 , 263 , 264 , 265 , 266 , 267 , 269 , 270 , 271 , 273 , 274 , 275 , 276 , 277 , 278 , 279 , 280 , 281 , 283 , 284 , 285 , 286 , 287 , 290 , 291 , 292 , 293 , 294 , 295 , 296 , 297 , 298 , 299 , 300 , 301 , 305 , 307 , 308 , 309 , 310 , 311 , 312 , 313 , 314 , 315 , 316 , 317 , 318 , 319 , 320 , 321 , 322 , 323 , 324 , 325 , 326 , 327 , 328 , 329 , 330 , 331 , 332 , 333 , 334 , 335 , 336 , 337 , 338 , 339 , 340 , 341 , 342 , 343 , 344 , 345 , 346 , 347 , 348 , 349 , 350 , 351 , 352 , 353 , 354 , 355 , 356 , 357 , 358 , 359 , 360 , 361 , 362 , 363 , 364 , 365 , 366 , 367 , 368 , 369 , 370 , 372 , 373 , 374 , 375 , 376 , 377 , 378 , 379 , 380 , 381 , 382 , 383 , 384 , 385 , 386 , 387 , 389 , 390 , 391 , 392 , 393 , 394 , 395 , 396 , 397 , 398 , 399 , 400 , 401 , 402 , 403 , 404 , 405 , 406 , 407 , 408 , 409 , 410 , 411 , 412 , 413 , 414 , 415 , 416 , 417 , 418 , 419 , 420 , 421 , 422 , 423 , 424 , 425 , 426 , 427 , 428 , 429 , 430 , 431 , 432 , 433 , 434 , 435 , 436 , 437 , 438 , 439 , 440 , 441 , 442 , 443 , 444 , 445 , 446 , 447 , 448 , 449 , 450 , 451 , 452 , 453 , 454 , 455 , 456 , 457 , 458 , 459 , 460 , 461 , 462 , 463 , 464 , 465 , 466 , 467 , 468 , 469 , 470 , 472 , 473 , 474 , 475 , 476 , 477 , 478 , 479 , 480 , 481 , 482 , 483 , 484 , 485 , 486 , 487 , 488 , 489 , 490 , 491 , 492 , 493 , 494 , 495 , 496 , 497 , 498 , 499 , 500 , 501 , 502 , 503 , 504 , 505 , 506 , 507 , 509 , 510 , 511 , 512 , 513 , 514 , 515 , 516 , 517 , 518 , 519 , 520 , 521 , 522 , 523 , 524 , 525 , 526 , 527 , 528 , 529 , 530 , 531 , 532 , 533 , 534 , 535 , 536 , 537 , 538 , 539 , 540 , 541 , 542 , 543 , 544 , 545 , 546 , 547 , 548 , 549 , 550 , 551 , 552 , 553 , 554 , 555 , 556 , 557 , 558 , 559 , 560 , 561 , 562 , 563 , 564 , 565 , 566 , 567 , 568 , 569 , 570 , 571 , 572 , 573 , 574 , 575 , 576 , 577 , 578 , 579 , 580 , 582 , 583 , 584 , 585 , 586 , 587 , 588 , 589 , 590 , 591 , 592 , 594 , 595 , 596 , 597 , 598 , 599 , 600 , 601 , 602 , 603 , 604 , 605 , 606 , 607 , 608 , 609 , 610 , 611 , 612 , 613 , 614 , 615 , 616 , 617 , 618 , 619 , 620 , 621 , 622 , 624 , 625 , 626 , 627 , 628 , 629 , 630 , 631 , 632 , 633 , 634 , 635 , 636 , 637 , 639 , 640 , 641 , 642 , 643 , 644 , 645 , 646 , 647 , 648 , 649 , 650 , 651 , 652 , 653 , 654 , 655 , 656 , 657 , 658 , 659 , 660 , 661 , 662 , 663 , 664 , 665 , 666 , 667 , 668 , 669 , 670 , 671 , 672 , 673 , 674 , 675 , 676 , 677 , 678 , 679 , 680 , 681 , 682 , 683 , 684 , 685 , 686 , 687 , 688 , 689 , 690 , 691 , 692 , 693 , 694 , 695 , 696 , 700 , 701 , 702 , 703 , 704 , 705 , 706 , 707 , 709 , 710 , 711 , 712 , 713 , 714 , 715 , 716 , 717 , 718 , 719 , 720 , 721 , 722 , 723 , 724 , 725 , 726 , 727 , 728 , 729 , 730 , 731 , 732 , 733 , 734 , 735 , 736 , 737 , 739 , 740 , 741 , 742 , 743 , 744 , 745 , 746 , 747 , 748 , 749 , 750 , 751 , 752 , 753 , 754 , 755 , 756 , 757 , 758 , 759 , 760 , 761 , 762 , 764 , 765 , 766 , 767 , 769 , 770 , 771 , 772 , 773 , 774 , 775 , 776 , 777 , 778 , 779 , 780 , 781 , 782 , 783 , 784 , 785 , 786 , 787 , 788 , 789 , 790 , 791 , 792 , 793 , 794 , 795 , 796 , 797 , 798 , 799 , 800 , 801 , 802 , 803 , 804 , 805 , 806 , 807 , 808 , 809 , 810 , 811 , 812 , 813 , 814 , 815 , 817 , 818 , 819 , 820 , 821 , 822 , 823 , 824 , 825 , 826 , 827 , 828 , 829 , 830 , 831 , 832 , 833 , 834 , 835 , 836 , 837 , 838 , 839 , 840 , 841 , 842 , 843 , 844 , 845 , 846 , 847 , 848 , 849 , 850 , 851 , 852 , 853 , 854 , 855 , 856 , 857 , 858 , 859 , 860 , 861 , 862 , 863 , 864 , 865 , 866 , 867 , 868 , 869 , 870 , 871 , 872 , 873 , 874 , 875 , 876 , 877 , 879 , 880 , 881 , 882 , 883 , 884 , 885 , 886 , 887 , 888 , 889 , 890 , 891 , 892 , 893 , 894 , 895 , 896 , 898 , 899 , 900 , 902 , 903 , 904 , 905 , 906 , 907 , 908 , 909 , 911 , 913 , 914 , 923 , 924 , 925 , 926 ) , mutation of modification site ( 22 , 25 , 52 , 738 , 816 , 897 , 917 , 919 ) , peptide sequencing ( 27 ) , phospho-antibody ( 12 , 13 , 15 , 17 , 20 , 21 , 22 , 23 , 24 , 25 , 27 , 28 , 29 , 30 , 31 , 33 , 35 , 37 , 38 , 40 , 41 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 51 , 52 , 55 , 56 , 59 , 61 , 73 , 79 , 81 , 88 , 93 , 95 , 96 , 105 , 115 , 118 , 125 , 126 , 153 , 163 , 167 , 175 , 214 , 217 , 218 , 249 , 260 , 268 , 272 , 282 , 288 , 289 , 294 , 302 , 303 , 304 , 306 , 371 , 471 , 508 , 581 , 593 , 638 , 697 , 699 , 708 , 763 , 768 , 816 , 878 , 897 , 901 , 910 , 912 , 915 , 916 , 917 , 918 , 919 , 920 , 921 , 922 , 927 , 928 , 929 , 931 , 932 , 934 , 935 , 936 , 937 , 939 , 940 , 941 ) , phosphoamino acid analysis ( 623 ) , western blotting ( 13 , 17 , 20 , 21 , 22 , 23 , 24 , 25 , 27 , 28 , 29 , 30 , 31 , 33 , 35 , 37 , 38 , 40 , 41 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 51 , 52 , 55 , 56 , 59 , 61 , 73 , 79 , 81 , 88 , 93 , 95 , 96 , 105 , 115 , 125 , 126 , 153 , 163 , 167 , 175 , 214 , 217 , 218 , 249 , 260 , 268 , 272 , 282 , 288 , 289 , 294 , 302 , 303 , 306 , 371 , 471 , 508 , 581 , 593 , 623 , 638 , 697 , 699 , 708 , 738 , 763 , 768 , 816 , 878 , 897 , 901 , 910 , 912 , 915 , 916 , 917 , 918 , 919 , 920 , 921 , 922 , 928 , 929 , 931 , 932 , 936 , 937 , 940 )
Disease tissue studied:
bone cancer ( 303 , 921 ) , brain cancer ( 28 , 105 , 260 , 272 , 303 , 910 , 915 ) , glioblastoma ( 28 , 105 , 272 , 303 , 910 , 915 ) , glioblastoma multiforme ( 915 ) , glioma ( 28 , 105 , 272 , 303 , 910 , 915 ) , Schwannoma ( 260 ) , breast cancer ( 24 , 27 , 32 , 33 , 35 , 45 , 53 , 55 , 56 , 82 , 105 , 153 , 218 , 302 , 303 , 578 , 579 , 916 , 922 , 928 ) , breast cancer, triple negative ( 55 , 105 ) , cervical cancer ( 153 , 936 ) , cervical squamous cell carcinoma ( 936 ) , colorectal cancer ( 31 , 116 , 117 , 153 , 214 , 413 , 420 , 421 , 423 , 581 ) , colorectal carcinoma ( 31 , 116 , 117 , 153 , 214 , 581 ) , endometrial cancer ( 175 ) , endometrial adenocarcinoma ( 175 ) , esophageal cancer ( 15 ) , esophageal carcinoma ( 15 ) , gallbladder cancer ( 552 ) , gallbladder carcinoma ( 552 ) , gastric cancer ( 90 , 91 , 92 , 119 , 128 , 129 , 130 , 131 , 132 , 133 , 134 , 135 , 136 , 137 , 138 , 139 , 141 , 142 , 143 , 144 , 145 , 146 , 147 , 148 , 158 , 162 , 212 , 213 , 242 , 243 , 247 , 248 , 252 , 253 , 271 , 274 , 275 , 298 , 299 , 305 , 553 , 612 , 625 , 626 , 823 , 825 , 826 , 827 ) , gastric carcinoma ( 90 , 91 , 92 , 119 , 128 , 129 , 130 , 131 , 132 , 133 , 134 , 135 , 136 , 137 , 138 , 139 , 141 , 142 , 143 , 144 , 145 , 146 , 147 , 148 , 158 , 162 , 212 , 213 , 242 , 243 , 247 , 248 , 252 , 253 , 271 , 274 , 275 , 298 , 299 , 305 , 612 , 625 , 626 , 823 , 825 , 826 , 827 ) , HNSCC ( 51 ) , kidney cancer ( 40 , 508 , 638 ) , leukemia ( 21 , 23 , 29 , 86 , 93 , 240 , 241 , 249 , 269 , 333 , 334 , 335 , 352 , 440 , 582 , 583 , 584 , 585 , 586 , 712 , 713 , 723 , 724 , 872 , 896 , 912 , 919 , 928 ) , acute myelogenous leukemia ( 86 , 333 , 334 , 335 , 352 , 928 ) , chronic lymphocytic leukemia ( 23 ) , chronic myelogenous leukemia ( 29 , 240 , 241 , 249 , 269 , 440 , 582 , 583 , 584 , 585 , 586 , 712 , 713 , 723 , 724 , 872 , 896 , 912 ) , T cell leukemia ( 21 , 23 , 93 , 919 ) , liver cancer ( 20 , 307 , 551 , 638 ) , hepatocellular carcinoma ( 20 ) , lung cancer ( 31 , 38 , 41 , 44 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 71 , 166 , 168 , 169 , 170 , 171 , 172 , 173 , 214 , 244 , 245 , 246 , 254 , 259 , 276 , 281 , 300 , 303 , 305 , 336 , 435 , 439 , 441 , 513 , 515 , 557 , 581 , 608 , 624 , 710 , 817 , 818 , 819 , 820 , 821 , 822 , 824 , 868 , 869 , 870 , 871 , 873 ) , mesothelioma ( 171 ) , non-small cell lung cancer ( 31 , 38 , 41 , 44 , 64 , 65 , 66 , 68 , 69 , 71 , 77 , 78 , 166 , 168 , 169 , 170 , 171 , 172 , 173 , 244 , 245 , 246 , 254 , 259 , 276 , 281 , 300 , 336 , 435 , 439 , 513 , 515 , 581 , 608 , 624 , 710 , 817 , 818 , 819 , 820 , 821 , 822 , 824 , 868 , 869 , 870 , 871 , 873 ) , non-small cell lung adenocarcinoma ( 38 , 41 , 64 , 65 , 66 , 67 , 68 , 69 , 71 , 78 , 169 , 170 , 173 , 245 , 254 , 276 , 281 , 305 , 439 , 515 , 608 , 624 ) , non-small cell lung adenocarcinoma, surrounding tissue ( 514 ) , non-small cell large cell lung carcinoma ( 41 , 65 , 68 , 166 ) , non-small cell squamous cell lung carcinoma ( 67 , 168 , 171 , 245 , 276 , 281 , 305 , 441 , 557 , 581 , 624 , 710 , 817 , 818 , 820 , 822 ) , non-small cell squamous cell lung carcinoma, surrounding tissue ( 556 ) , small-cell lung cancer ( 62 , 63 ) , lymphoma ( 21 , 25 , 48 , 93 , 115 , 268 ) , anaplastic large cell lymphoma ( 268 ) , B cell lymphoma ( 25 , 48 , 93 ) , Hodgkin's lymphoma ( 21 ) , non-Hodgkin's lymphoma ( 25 , 48 , 93 ) , mantle cell lymphoma ( 25 , 48 , 93 ) , PEL ( 115 ) , T cell lymphoma ( 268 ) , neuroblastoma ( 42 , 163 , 255 , 256 , 283 , 284 , 285 , 286 , 465 , 466 , 910 ) , ovarian cancer ( 105 , 126 , 153 , 177 , 260 , 933 ) , pancreatic cancer ( 929 ) , pancreatic carcinoma ( 929 ) , pancreatic ductal adenocarcinoma ( 60 ) , prostate cancer ( 126 , 153 ) , Kaposi's sarcoma ( 115 ) , melanoma skin cancer ( 39 , 52 , 322 , 323 , 324 , 438 , 442 , 443 , 445 , 554 , 555 , 570 , 571 , 587 , 588 ) , fibrosarcoma of soft tissue ( 214 ) , leiomyosarcoma ( 175 ) , rhabdomyosarcoma ( 43 ) , cancer, squamous cell carcinoma ( 20 ) , teratoma ( 263 ) , neurofibromatosis type 1 ( 289 ) , tuberous sclerosis ( 638 )
Relevant cell line - cell type - tissue:
'granulosa, luteal' ( 282 ) , 'muscle, skeletal' ( 61 , 94 , 931 , 934 ) , 'muscle, smooth' ( 931 ) , 'neuron, cortical'-brain ( 125 ) , 'pancreatic, ductal'-pancreas ( 60 ) , 'stem, embryonic' ( 88 ) , 293 (epithelial) [AT1 (human), transfection] ( 219 ) , 293 (epithelial) [Raptor (human), transfection] ( 167 ) , 293 (epithelial) ( 52 , 56 , 105 , 288 , 303 , 306 , 371 , 464 , 468 , 469 , 470 , 472 , 473 , 474 , 475 , 476 , 499 , 593 , 623 , 738 , 917 ) , 293E (epithelial) ( 816 ) , 786-O (renal) [VHL (human), transfection] ( 34 ) , 786-O (renal) ( 40 ) , A2780 (ovarian) ( 153 ) , A375 (melanocyte) ( 52 ) , A431 (epithelial) ( 768 ) , A498 (renal) ( 258 ) , A549 (pulmonary) ( 38 , 41 , 64 , 214 , 303 , 581 , 608 ) , AN3-CA (endometrial) ( 175 ) , B lymphocyte-blood ( 919 ) , BaF3 ('B lymphocyte, precursor') ( 249 ) , bone marrow ( 37 , 333 , 334 , 335 , 352 ) , brain ( 17 , 910 ) , breast ( 578 , 579 ) , BT-20 (breast cell) ( 105 ) , BT-474 (breast cell) ( 27 , 32 , 153 ) , BV-173 (myeloid) ( 249 , 912 ) , C2C12 (myoblast) ( 931 ) , C33-A (cervical) ( 153 ) , Caki-1 (renal) ( 508 ) , Cal-12T (pulmonary) ( 71 ) , Cal27 (squamous) ( 51 ) , Calu-3 (pulmonary) ( 66 ) , Capan2 (pancreatic) ( 30 ) , CEF ( 22 ) , COLO-829 (melanocyte) ( 52 ) , colon ( 413 , 420 , 421 , 423 ) , COS (fibroblast) ( 809 , 897 ) , DMS153 (pulmonary) ( 69 ) , DMS53 (pulmonary) ( 63 ) , DMS79 (pulmonary) ( 62 ) , DU 145 (prostate cell) ( 768 ) , Flp-In T-Rex-293 (epithelial) [PRKD1 (human), genetic knockin] ( 84 ) , Flp-In T-Rex-293 (epithelial) ( 84 ) , glial ( 638 ) , GM00130 (B lymphocyte) ( 257 ) , GRANTA-519 (B lymphocyte) ( 25 ) , granulocyte-blood ( 86 ) , HaCaT (keratinocyte) ( 59 ) , HAEC (endothelial) ( 697 ) , HCC1428 (breast cell) ( 24 ) , HCC15 (pulmonary) ( 67 ) , HCC1500 (breast cell) ( 24 ) , HCC1806 (breast cell) ( 55 ) , HCC44 (pulmonary) ( 71 ) , HCC78 (pulmonary) ( 68 ) , HCC827 (pulmonary) ( 66 ) , HCT116 (intestinal) ( 31 , 116 , 117 , 153 , 214 , 581 ) , HDLM-2 (lymphoid) ( 21 ) , heart ( 940 ) , HEC-1-A (endometrial) ( 175 ) , HEC-50B (endometrial) ( 175 ) , HEI-193 (Schwann) ( 260 ) , HEK293-A (epithelial) ( 12 ) , HEK293T (epithelial) ( 79 , 95 , 96 , 878 , 897 , 908 ) , HeLa (cervical) ( 26 , 43 , 47 , 50 , 73 , 80 , 125 , 149 , 174 , 214 , 272 , 277 , 278 , 279 , 280 , 294 , 321 , 337 , 338 , 339 , 340 , 341 , 342 , 343 , 344 , 345 , 346 , 347 , 348 , 349 , 350 , 351 , 353 , 354 , 355 , 356 , 357 , 358 , 359 , 360 , 361 , 362 , 363 , 364 , 365 , 366 , 367 , 368 , 369 , 370 , 372 , 373 , 374 , 375 , 376 , 377 , 378 , 379 , 380 , 381 , 382 , 383 , 444 , 446 , 447 , 448 , 449 , 450 , 451 , 452 , 453 , 454 , 455 , 456 , 457 , 458 , 459 , 460 , 461 , 462 , 471 , 602 , 722 , 768 , 816 , 911 ) , Hep3B (hepatic) ( 20 ) , HepG2 (hepatic) ( 387 , 389 ) , HMLER ('stem, breast cancer') [CXCR4 (human), knockdown] ( 53 ) , HMLER ('stem, breast cancer') ( 53 ) , HMVEC (endothelial) ( 939 ) , Hs852.T (melanocyte) ( 52 ) , HT-29 (intestinal) ( 926 ) , HT1080 (fibroblast) ( 214 ) , hTERT-RPE1 (epithelial) ( 306 ) , Huh7 (hepatic) ( 20 , 551 ) , IMR32 (neural crest) ( 910 ) , Ishikawa (endometrial) ( 175 ) , JEKO-1 (B lymphocyte) ( 25 , 48 , 93 ) , Jurkat (T lymphocyte) ( 21 , 23 , 70 , 74 , 85 , 87 , 89 , 93 , 97 , 98 , 99 , 100 , 101 , 102 , 103 , 104 , 106 , 107 , 108 , 109 , 110 , 111 , 112 , 113 , 114 , 120 , 121 , 122 , 123 , 124 , 127 , 150 , 151 , 152 , 154 , 155 , 156 , 157 , 159 , 160 , 161 , 164 , 165 , 176 , 179 , 180 , 181 , 182 , 183 , 184 , 185 , 186 , 187 , 188 , 189 , 190 , 191 , 192 , 193 , 194 , 195 , 196 , 197 , 198 , 199 , 200 , 201 , 202 , 203 , 204 , 205 , 206 , 207 , 208 , 209 , 210 , 211 , 215 , 216 , 217 , 220 , 221 , 222 , 223 , 224 , 225 , 226 , 227 , 228 , 229 , 230 , 231 , 232 , 233 , 234 , 235 , 236 , 237 , 238 , 239 , 250 , 251 , 261 , 262 , 265 , 266 , 267 , 270 , 273 , 287 , 290 , 291 , 292 , 293 , 295 , 296 , 297 , 301 , 308 , 309 , 310 , 311 , 312 , 313 , 314 , 315 , 316 , 317 , 318 , 319 , 320 , 325 , 327 , 328 , 329 , 330 , 331 , 332 , 390 , 391 , 392 , 393 , 394 , 395 , 396 , 397 , 398 , 399 , 403 , 404 , 405 , 406 , 407 , 408 , 409 , 410 , 411 , 412 , 414 , 415 , 416 , 417 , 418 , 419 , 422 , 424 , 425 , 426 , 427 , 428 , 429 , 430 , 436 , 437 , 467 , 477 , 486 , 487 , 488 , 489 , 490 , 491 , 492 , 493 , 494 , 495 , 496 , 497 , 498 , 509 , 510 , 519 , 536 , 537 , 538 , 562 , 563 , 569 , 580 , 603 , 604 , 605 , 607 , 663 , 664 , 665 , 670 , 694 , 695 , 696 , 700 , 709 , 711 , 714 , 715 , 716 , 717 , 718 , 719 , 720 , 721 , 727 , 728 , 729 , 760 , 761 , 762 , 772 , 773 , 774 , 775 , 776 , 777 , 778 , 779 , 780 , 781 , 782 , 783 , 784 , 785 , 786 , 787 , 788 , 797 , 798 , 799 , 800 , 810 , 811 , 812 , 813 , 814 , 815 , 840 , 841 , 842 , 843 , 844 , 853 , 854 , 855 , 856 , 857 , 858 , 859 , 860 , 876 , 877 , 886 , 887 , 898 , 902 , 903 , 904 , 905 , 906 , 907 , 909 , 923 , 924 , 925 , 932 ) , K562 (erythroid) ( 29 , 80 , 240 , 241 , 249 , 269 , 321 , 385 , 386 , 440 , 582 , 583 , 584 , 585 , 586 , 606 , 712 , 713 , 723 , 724 , 725 , 726 , 730 , 731 , 764 , 765 , 766 , 767 , 770 , 771 , 789 , 790 , 791 , 792 , 793 , 794 , 795 , 796 , 845 , 846 , 847 , 848 , 849 , 850 , 851 , 852 , 865 , 872 , 879 , 880 , 881 , 882 , 883 , 884 , 885 , 888 , 889 , 890 , 891 , 892 , 893 , 894 , 895 , 896 , 899 , 900 , 912 , 927 ) , Karpas-299 (T lymphocyte) ( 268 ) , KB (squamous) ( 936 ) , KCL22 (myeloid) ( 29 ) , KELLY (neural crest) ( 910 ) , kidney ( 306 , 508 , 638 ) , Kit225 (T lymphocyte) ( 919 ) , KLE (endometrial) ( 175 ) , KM-H2 (lymphoid) ( 21 ) , KPL-1 (breast cell) ( 153 ) , Kyse150 (esophageal) ( 15 ) , Kyse30 (esophageal) ( 15 ) , Kyse410 (esophageal) ( 15 ) , L1236 (lymphoid) ( 21 ) , L428 (lymphoid) ( 21 ) , L540 (lymphoid) ( 21 ) , LAMA84 (myeloid) ( 927 ) , LAN-6 (neural crest) ( 42 , 283 , 465 , 466 ) , liver ( 57 , 307 , 638 ) , LLC-PK1 (renal) ( 918 ) , LN229 (glial) ( 28 ) , LOU-NH91 (squamous) ( 67 ) , LS-513 (intestinal) ( 153 ) , lung ( 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 71 , 300 , 304 , 336 , 435 , 441 , 513 , 514 , 515 , 556 , 557 ) , lymphocyte-blood ( 86 ) , lymphoid ( 93 ) , M059K (glial) ( 913 , 914 ) , MCF-10A (breast cell) ( 35 , 56 ) , MCF-7 (breast cell) ( 24 , 32 , 35 , 45 , 56 , 153 , 302 , 303 , 768 , 916 , 922 , 928 ) , MDA-MB-231 (breast cell) ( 27 , 45 , 153 ) , MEF (fibroblast) [Etk (human), heterozygous knockout] ( 81 ) , MEF (fibroblast) [TSC22D2 (human)] ( 768 ) , MEF (fibroblast) ( 35 , 47 , 95 , 125 , 288 , 638 , 917 ) , MIA PaCa (pancreatic) ( 768 ) , MKN-45 (gastric) ( 83 , 90 , 91 , 92 , 119 , 128 , 129 , 130 , 131 , 132 , 133 , 134 , 135 , 136 , 137 , 138 , 139 , 141 , 142 , 143 , 144 , 145 , 146 , 147 , 148 , 158 , 162 , 212 , 213 , 242 , 243 , 247 , 248 , 252 , 253 , 271 , 274 , 275 , 298 , 299 , 305 , 431 , 432 , 433 , 434 , 511 , 512 , 539 , 540 , 541 , 542 , 543 , 544 , 545 , 546 , 547 , 548 , 549 , 550 , 564 , 565 , 566 , 567 , 568 , 589 , 590 , 609 , 610 , 611 , 612 , 613 , 614 , 615 , 616 , 617 , 625 , 626 , 701 , 702 , 769 , 801 , 802 , 803 , 804 , 805 , 806 , 807 , 808 , 823 , 825 , 826 , 827 , 832 , 833 , 838 , 839 , 866 , 867 , 874 , 875 ) , mononuclear-blood ( 23 ) , MV4-11 (macrophage) ( 384 ) , myeloid-bone marrow ( 37 ) , myocyte-heart ( 937 ) , NB-4 (myeloid) ( 928 , 935 ) , NCCIT (epithelial) ( 263 ) , NCI-H128 (pulmonary) ( 62 ) , NCI-H1299 (pulmonary) ( 31 , 65 , 581 ) , NCI-H1355 (pulmonary) ( 64 ) , NCI-H1417 (pulmonary) ( 62 ) , NCI-H1437 (pulmonary) ( 69 , 71 ) , NCI-H157 (pulmonary) ( 31 ) , NCI-H1650 (pulmonary) ( 66 , 259 , 326 , 581 ) , NCI-H1651 (pulmonary) ( 172 ) , NCI-H1666 (pulmonary) ( 71 ) , NCI-H1703 (squamous) ( 67 , 83 , 245 , 276 , 281 , 305 , 400 , 401 , 402 , 478 , 479 , 480 , 481 , 482 , 483 , 484 , 485 , 500 , 501 , 502 , 503 , 504 , 505 , 506 , 507 , 558 , 559 , 560 , 561 , 581 , 591 , 592 , 594 , 595 , 596 , 597 , 598 , 599 , 600 , 601 , 624 , 710 , 817 , 818 , 820 , 822 , 828 , 829 , 834 , 835 , 861 , 862 , 868 , 869 ) , NCI-H1734 (pulmonary) ( 65 ) , NCI-H1781 (pulmonary) ( 68 ) , NCI-H1792 (pulmonary) ( 64 ) , NCI-H1944 (pulmonary) ( 65 ) , NCI-H1975 (pulmonary) ( 66 , 173 ) , NCI-H2073 (pulmonary) ( 67 , 69 ) , NCI-H209 (pulmonary) ( 62 , 69 ) , NCI-H2106 (pulmonary) ( 66 ) , NCI-H2170 (squamous) ( 168 ) , NCI-H2228 (pulmonary) ( 68 , 78 , 439 , 522 ) , NCI-H226 (pulmonary) ( 171 ) , NCI-H23 (pulmonary) ( 64 , 581 ) , NCI-H2342 (pulmonary) ( 67 , 170 ) , NCI-H2405 (pulmonary) ( 71 ) , NCI-H3122 (pulmonary) ( 68 , 77 , 169 ) , NCI-H3255 (pulmonary) ( 83 , 244 , 246 , 305 , 524 , 525 , 526 , 527 , 528 , 529 , 530 , 531 , 532 , 533 , 534 , 535 , 819 , 821 , 824 , 830 , 831 , 836 , 837 , 863 , 864 , 870 , 871 , 873 ) , NCI-H358 (pulmonary) ( 65 ) , NCI-H441 (pulmonary) ( 64 , 254 ) , NCI-H446 (pulmonary) ( 63 ) , NCI-H460 (pulmonary) ( 41 , 65 , 166 , 581 , 768 ) , NCI-H524 (pulmonary) ( 62 ) , NCI-H526 (pulmonary) ( 63 ) , NCI-H661 (pulmonary) ( 68 ) , NCI-H69 (pulmonary) ( 63 ) , NCI-H82 (pulmonary) ( 63 ) , NCI-H838 (pulmonary) ( 69 ) , neuron-'brain, cerebral cortex' ( 897 ) , NT2 (testicular) ( 264 ) , OCUG-1 ( 552 ) , oocyte ( 763 ) , ovarian ( 763 ) , ovary ( 933 ) , OVCAR3 (ovarian) ( 126 ) , OVCAR4 (ovarian) ( 933 ) , OVCAR5 (ovarian) ( 933 ) , OVKATE (ovarian) ( 177 ) , pancreas ( 929 ) , PC3 (prostate cell) ( 126 , 153 , 768 ) , prostate ( 118 ) , RCC4 (renal) ( 508 ) , Rh30 ('muscle, skeletal') ( 43 ) , salivary gland ( 463 ) , SH-SY5Y (neural crest) ( 42 , 163 , 256 , 285 , 286 , 910 ) , SHEP (neuron) ( 910 ) , SK-N-BE(2) (neural crest) ( 42 , 910 ) , SKBr3 (breast cell) ( 27 , 82 ) , skin ( 322 , 323 , 324 , 438 , 442 , 443 , 445 , 554 , 555 , 570 , 571 , 587 , 588 ) , SKNSH (neural crest) ( 910 ) , SKOV-3 (ovarian) ( 105 , 126 , 260 , 933 ) , SKUT-1 ( 175 ) , SMS-KCN-A (neural crest) ( 42 , 255 , 284 ) , SR (T lymphocyte) ( 268 ) , ST88-14 (neuron) ( 289 ) , stomach ( 553 ) , SU-DHL1 (T lymphocyte) ( 268 ) , SW1463 (intestinal) ( 153 ) , T lymphocyte ( 13 ) , T lymphocyte-blood ( 901 , 919 ) , T47D (breast cell) ( 24 , 33 , 153 , 218 ) , T98G (glial) ( 915 ) , U-251 MG (glial) ( 272 ) , U2OS (bone cell) ( 303 , 921 ) , U87MG (glial) ( 105 , 303 , 910 ) , UMUC6 (bladder cell) ( 51 ) , vascular smooth muscle cell ('muscle, smooth') ( 708 ) , VSMC-aorta ( 920 ) , WM239A (melanocyte) ( 39 ) , Z138 (B lymphocyte) ( 48 )

Upstream Regulation
Regulatory protein:
ACSL4 (human) ( 33 ) , Akt1 (human) ( 699 ) , ARF GAP1 (human) ( 12 ) , CAB39 (human) ( 272 ) , caveolin-1 (human) ( 118 ) , CIP2A (human) ( 56 ) , Etk (human) ( 81 ) , FLCN (human) ( 73 ) , GSK3A (human) ( 35 ) , GSK3B (human) ( 35 , 55 ) , HRas (human) ( 816 ) , IL2RA (human) ( 901 ) , LKB1 (human) ( 581 ) , LYN (human) ( 698 ) , MAGE-A6 (human) ( 46 ) , MAGEA3 (human) ( 46 ) , MEK1 (human) ( 816 ) , mTOR (human) ( 268 , 697 ) , PDK1 (human) ( 24 , 153 , 371 ) , PIK3CA (human) ( 371 ) , PIK3R2 (human) ( 22 ) , Pim1 (human) ( 21 ) , Pim2 (human) ( 21 ) , PKCA (human) ( 217 ) , PKD1 (human) ( 306 ) , PLK1 (human) ( 921 ) , Raptor (human) ( 56 ) , RHEB (human) ( 917 ) , RICTOR (mouse) ( 288 ) , SESN1 (human) ( 593 ) , SESN2 (mouse) ( 593 ) , TRAF2 (human) ( 45 ) , TRAF4 (human) ( 45 ) , TSC1 (human) ( 916 , 921 ) , TSC2 (human) ( 916 , 921 ) , ULK1 (human) ( 878 ) , ULK2 (human) ( 878 )
Putative in vivo kinases:
mTOR (human) ( 96 ) , p70S6K (human) ( 816 ) , p90RSK (human) ( 816 ) , PKCD (human) ( 928 )
Kinases, in vitro:
p70S6K (human) ( 816 ) , p90RSK (human) ( 816 ) , RSK2 (human) ( 816 )
Putative upstream phosphatases:
PPP5C (human) ( 294 )
Treatments:
1-azakenpaullone ( 55 ) , 2-deoxyglucose ( 214 , 936 ) , 4-HT ( 699 ) , 5(S)-HETE ( 939 ) , 5-HT ( 920 ) , A-443654 ( 768 ) , acalabrutinib ( 23 ) , activin ( 88 ) , AG1478 ( 930 ) , AG490 ( 939 ) , alpelisib ( 28 ) , AMDE-1 ( 47 ) , amino_acid_starvation ( 56 , 73 , 936 ) , amino_acids ( 73 , 288 , 471 ) , angiotensin ( 930 ) , angiotensin_2 ( 918 ) , anti-CD3/CD28 ( 901 , 932 ) , anti-HLA ( 697 ) , anti-IgM ( 25 ) , AR-A014418 ( 55 ) , arginine deprivation ( 13 ) , As2O3 ( 912 ) , AZD8055 ( 20 , 38 , 303 ) , batimastat ( 918 ) , BI2536 ( 174 ) , bisindolylmaleimide ( 937 ) , bleomycin ( 294 ) , caffeine ( 163 ) , chrysin ( 15 ) , colforsin ( 95 , 940 ) , compound 2 ( 153 ) , compound_7 ( 153 ) , CRM197 ( 918 ) , dactolisib ( 175 ) , dinoprost ( 282 ) , DMSO ( 699 ) , EGF ( 26 , 79 , 218 , 321 , 911 , 918 , 931 ) , Epo ( 738 ) , estradiol ( 916 ) , exercise ( 934 ) , fasting ( 61 ) , fluoromethylketone ( 816 ) , FTI277 ( 916 ) , gefitinib ( 59 , 83 , 305 ) , glucose ( 941 ) , glucose_starvation ( 214 ) , GSK2334470 ( 24 ) , H-89 ( 95 ) , H2O2 ( 306 ) , heregulin ( 88 ) , IBMX ( 95 ) , ibrutinib ( 23 ) , idelalisib ( 25 ) , IFN-gamma ( 935 ) , IGF-1 ( 43 , 88 , 910 ) , imatinib ( 29 , 83 , 249 , 305 , 927 ) , INK-128 ( 31 , 38 ) , insulin ( 61 , 288 , 302 , 371 , 816 , 931 , 936 , 937 , 940 , 941 , 942 ) , ionizing_radiation ( 257 , 922 ) , KPT-185 ( 48 ) , lapatinib ( 27 , 51 , 82 ) , leucine ( 105 ) , LY294002 ( 51 , 88 , 288 , 289 , 912 , 915 , 919 , 928 , 933 , 935 , 938 , 939 ) , medium change ( 471 ) , metastatic potential ( 178 ) , metformin ( 763 ) , miR-451 ( 272 ) , MPA ( 927 ) , nitric_oxide ( 125 ) , OSI-027 ( 93 , 249 ) , P529 ( 140 ) , palbociclib ( 30 ) , PD184352 ( 931 ) , PD98059 ( 942 ) , PF-04691502 ( 105 ) , phorbol_ester ( 44 , 49 , 86 , 167 , 302 , 623 , 816 , 937 , 940 ) , PI-103 ( 105 , 126 , 288 ) , PP242 ( 27 ) , QLT0254 ( 929 ) , RAD001 ( 126 ) , rapamycin ( 13 , 35 , 40 , 41 , 43 , 49 , 55 , 86 , 93 , 96 , 105 , 126 , 249 , 282 , 288 , 289 , 302 , 303 , 305 , 451 , 623 , 699 , 708 , 768 , 816 , 912 , 915 , 916 , 922 , 928 , 931 , 933 , 935 , 936 , 940 ) , retinoic_acid ( 928 ) , RGD ( 937 ) , ribociclib ( 24 ) , Ro31-8220 ( 51 , 936 ) , rosiglitazone ( 33 ) , SB203580 ( 915 ) , SB216763 ( 41 ) , SEL24-B489 ( 21 ) , seliciclib ( 897 ) , sertraline ( 20 ) , serum ( 371 , 816 , 915 , 917 , 938 ) , serum_starvation ( 73 , 306 , 471 ) , SGI-1776 ( 28 ) , SHP2_inhibitor ( 20 ) , siRNA ( 581 , 698 , 917 , 921 ) , Su11274 ( 83 , 305 ) , SU6656 ( 699 ) , temsirolimus ( 175 ) , testosterone ( 118 ) , Torin1 ( 38 , 49 , 73 , 96 ) , U0126 ( 49 , 167 , 218 , 282 , 302 , 305 , 321 , 738 , 816 , 915 , 936 , 937 ) , vanadate ( 938 ) , vemurafenib ( 39 ) , wortmannin ( 218 , 305 , 916 , 931 , 936 , 937 ) , XL413 ( 20 )

Downstream Regulation
Effects of modification on S6:
activity, induced ( 304 ) , enzymatic activity, induced ( 304 ) , molecular association, regulation ( 816 )
Effects of modification on biological processes:
cell growth, induced ( 45 , 118 ) , signaling pathway regulation ( 105 , 118 )
Induce interaction with:
RNA ( 816 )

Disease / Diagnostics Relevance
Relevant diseases:
Kaposi's sarcoma ( 115 ) , Status epilepticus ( 17 )

References 

1

Wang Y, et al. (2021) Phenotypic characterization of patients with activated PI3Kδ syndrome 1 presenting with features of systemic lupus erythematosus. Genes Dis 8, 907-917
34522717   Curated Info

2

Li Y, et al. (2021) FGFR-inhibitor-mediated dismissal of SWI/SNF complexes from YAP-dependent enhancers induces adaptive therapeutic resistance. Nat Cell Biol 23, 1187-1198
34737445   Curated Info

3

van der Vlist M, et al. (2021) Signaling by the inhibitory receptor CD200R is rewired by type I interferon. Sci Signal 14, eabb4324
34637328   Curated Info

4

Amin AG, et al. (2021) Targeting the mTOR pathway using novel ATP‑competitive inhibitors, Torin1, Torin2 and XL388, in the treatment of glioblastoma. Int J Oncol 59
34523696   Curated Info

5

Evans KW, et al. (2021) Oxidative phosphorylation is a metabolic vulnerability in chemotherapy-resistant triple negative breast cancer. Cancer Res
34518211   Curated Info

6

Lupse B, et al. (2021) Inhibition of PHLPP1/2 phosphatases rescues pancreatic β-cells in diabetes. Cell Rep 36, 109490
34348155   Curated Info

7

Kirstein AS, et al. (2021) PTEN regulates adipose progenitor cell growth, differentiation, and replicative aging. J Biol Chem 297, 100968
34273354   Curated Info

8

Gómez Tejeda Zañudo J, et al. (2021) Cell line-specific network models of ER+ breast cancer identify potential PI3Kα inhibitor resistance mechanisms and drug combinations. Cancer Res
34257082   Curated Info

9

Zhang EB, et al. (2021) Antifungal agent Terbinafine restrains tumor growth in preclinical models of hepatocellular carcinoma via AMPK-mTOR axis. Oncogene
34247189   Curated Info

10

Mora S, Adegoke OAJ (2021) The effect of a chemotherapy drug cocktail on myotube morphology, myofibrillar protein abundance, and substrate availability. Physiol Rep 9, e14927
34197700   Curated Info

11

Cerezo EL, et al. (2021) RIOK2 phosphorylation by RSK promotes synthesis of the human small ribosomal subunit. PLoS Genet 17, e1009583
34125833   Curated Info

12

Meng D, et al. (2021) ArfGAP1 inhibits mTORC1 lysosomal localization and activation. EMBO J, e106412
33988249   Curated Info

13

Crump NT, et al. (2021) Chromatin accessibility governs the differential response of cancer and T cells to arginine starvation. Cell Rep 35, 109101
33979616   Curated Info

14

Dai X, et al. (2021) Energy status dictates PD-L1 protein abundance and anti-tumor immunity to enable checkpoint blockade. Mol Cell
33909988   Curated Info

15

Chen J, et al. (2021) Chrysin serves as a novel inhibitor of DGK/FAK interaction to suppress the malignancy of esophageal squamous cell carcinoma (ESCC). Acta Pharm Sin B 11, 143-155
33532186   Curated Info

16

Mrozek EM, et al. (2021) Evaluation of Hsp90 and mTOR inhibitors as potential drugs for the treatment of TSC1/TSC2 deficient cancer. PLoS One 16, e0248380
33891611   Curated Info

17

Reynolds CD, et al. (2020) Increased expression of Fragile X mental retardation protein in malformative lesions of patients with focal cortical dysplasia. Neuroreport 31, 1036-1041
32833881   Curated Info

18

Michalopoulou E, et al. (2020) Macropinocytosis Renders a Subset of Pancreatic Tumor Cells Resistant to mTOR Inhibition. Cell Rep
32101748   Curated Info

19

Wen PY, et al. (2020) First-in-Human Phase I Study to Evaluate the Brain-Penetrant PI3K/mTOR Inhibitor GDC-0084 in Patients with Progressive or Recurrent High-Grade Glioma. Clin Cancer Res
31937616   Curated Info

20

Wang C, et al. (2019) Inducing and exploiting vulnerabilities for the treatment of liver cancer. Nature 574, 268-272
31578521   Curated Info

21

Szydłowski M, et al. (2017) Expression of PIM kinases in Reed-Sternberg cells fosters immune privilege and tumor cell survival in Hodgkin lymphoma. Blood 130, 1418-1429
28698206   Curated Info

22

Ito Y, Vogt PK, Hart JR (2017) Domain analysis reveals striking functional differences between the regulatory subunits of phosphatidylinositol 3-kinase (PI3K), p85α and p85β. Oncotarget 8, 55863-55876
28915558   Curated Info

23

Patel V, et al. (2017) Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells. Clin Cancer Res 23, 3734-3743
28034907   Curated Info

24

Jansen VM, et al. (2017) Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer. Cancer Res 77, 2488-2499
28249908   Curated Info

25

Yang Q, et al. (2017) Idelalisib Impacts Cell Growth through Inhibiting Translation-Regulatory Mechanisms in Mantle Cell Lymphoma. Clin Cancer Res 23, 181-192
27342398   Curated Info

26

Huang H, et al. (2016) Simultaneous Enrichment of Cysteine-containing Peptides and Phosphopeptides Using a Cysteine-specific Phosphonate Adaptable Tag (CysPAT) in Combination with titanium dioxide (TiO2) Chromatography. Mol Cell Proteomics 15, 3282-3296
27281782   Curated Info

27

Morrison Joly M, et al. (2016) Rictor/mTORC2 Drives Progression and Therapeutic Resistance of HER2-Amplified Breast Cancers. Cancer Res 76, 4752-64
27197158   Curated Info

28

Iqbal A, et al. (2016) Targeting of glioblastoma cell lines and glioma stem cells by combined PIM kinase and PI3K-p110α inhibition. Oncotarget 7, 33192-201
27120806   Curated Info

29

Salizzato V, et al. (2016) Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies. Oncotarget 7, 18204-18
26919095   Curated Info

30

Franco J, et al. (2016) Metabolic Reprogramming of Pancreatic Cancer Mediated by CDK4/6 Inhibition Elicits Unique Vulnerabilities. Cell Rep 14, 979-90
26804906   Curated Info

31

Li S, et al. (2016) Inhibition of mTOR complex 2 induces GSK3/FBXW7-dependent degradation of sterol regulatory element-binding protein 1 (SREBP1) and suppresses lipogenesis in cancer cells. Oncogene 35, 642-50
25893295   Curated Info

32

Carrier M, et al. (2016) Phosphoproteome and Transcriptome of RA-Responsive and RA-Resistant Breast Cancer Cell Lines. PLoS One 11, e0157290
27362937   Curated Info

33

Orlando UD, et al. (2015) Acyl-CoA synthetase-4, a new regulator of mTOR and a potential therapeutic target for enhanced estrogen receptor function in receptor-positive and -negative breast cancer. Oncotarget 6, 42632-50
26536660   Curated Info

34

Malec V, Coulson JM, Urbé S, Clague MJ (2015) Combined Analyses of the VHL and Hypoxia Signaling Axes in an Isogenic Pairing of Renal Clear Cell Carcinoma Cells. J Proteome Res 14, 5263-72
26506913   Curated Info

35

Azoulay-Alfaguter I, et al. (2015) Combined regulation of mTORC1 and lysosomal acidification by GSK-3 suppresses autophagy and contributes to cancer cell growth. Oncogene 34, 4613-23
25500539   Curated Info

36

Masui K, et al. (2015) Glucose-dependent acetylation of Rictor promotes targeted cancer therapy resistance. Proc Natl Acad Sci U S A 112, 9406-11
26170313   Curated Info

37

Shojaee S, et al. (2015) Erk Negative Feedback Control Enables Pre-B Cell Transformation and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia. Cancer Cell 28, 114-28
26073130   Curated Info

38

Koo J, et al. (2015) mTOR Complex 2 Stabilizes Mcl-1 Protein by Suppressing Its Glycogen Synthase Kinase 3-Dependent and SCF-FBXW7-Mediated Degradation. Mol Cell Biol 35, 2344-55
25918246   Curated Info

39

Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615
25850435   Curated Info

40

Liu XD, et al. (2015) Autophagy mediates HIF2α degradation and suppresses renal tumorigenesis. Oncogene 34, 2450-60
24998849   Curated Info

41

Koo J, et al. (2015) GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth. Oncotarget 6, 8974-87
25797247   Curated Info

42

Palacios-Moreno J, et al. (2015) Neuroblastoma Tyrosine Kinase Signaling Networks Involve FYN and LYN in Endosomes and Lipid Rafts. PLoS Comput Biol 11, e1004130
25884760   Curated Info

43

Chen L, et al. (2015) Both mTORC1 and mTORC2 are involved in the regulation of cell adhesion. Oncotarget 6, 7136-50
25762619   Curated Info

44

Ni Y, et al. (2015) PKD1 is downregulated in non-small cell lung cancer and mediates the feedback inhibition of mTORC1-S6K1 axis in response to phorbol ester. Int J Biochem Cell Biol 60, 34-42
25578563   Curated Info

45

Ren HY, et al. (2015) Cytoplasmic TRAF4 contributes to the activation of p70s6k signaling pathway in breast cancer. Oncotarget 6, 4080-96
25738361   Curated Info

46

Pineda CT, et al. (2015) Degradation of AMPK by a cancer-specific ubiquitin ligase. Cell 160, 715-28
25679763   Curated Info

47

Li M, et al. (2015) AMDE-1 is a dual function chemical for autophagy activation and inhibition. PLoS One 10, e0122083
25894744   Curated Info

48

Tabe Y, et al. (2015) Ribosomal Biogenesis and Translational Flux Inhibition by the Selective Inhibitor of Nuclear Export (SINE) XPO1 Antagonist KPT-185. PLoS One 10, e0137210
26340096   Curated Info

49

Leontieva OV, Blagosklonny MV (2014) Tumor promoter-induced cellular senescence: cell cycle arrest followed by geroconversion. Oncotarget 5, 12715-27
25587030   Curated Info

50

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

51

Axelrod MJ, et al. (2014) p70S6 kinase is a critical node that integrates HER-family and PI3 kinase signaling networks. Cell Signal 26, 1627-35
24662264   Curated Info

52

Galan JA, et al. (2014) Phosphoproteomic analysis identifies the tumor suppressor PDCD4 as a RSK substrate negatively regulated by 14-3-3. Proc Natl Acad Sci U S A 111, E2918-27
25002506   Curated Info

53

Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90
24782546   Curated Info

54

Hong S, et al. (2014) Cross-talk between sirtuin and mammalian target of rapamycin complex 1 (mTORC1) signaling in the regulation of S6 kinase 1 (S6K1) phosphorylation. J Biol Chem 289, 13132-41
24652283   Curated Info

55

Shin S, et al. (2014) Glycogen synthase kinase-3β positively regulates protein synthesis and cell proliferation through the regulation of translation initiation factor 4E-binding protein 1. Oncogene 33, 1690-9
23584478   Curated Info

56

Puustinen P, et al. (2014) CIP2A oncoprotein controls cell growth and autophagy through mTORC1 activation. J Cell Biol 204, 713-27
24590173   Curated Info

57

Bian Y, et al. (2014) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics 96, 253-62
24275569   Curated Info

58

Ullal AV, et al. (2014) Cancer cell profiling by barcoding allows multiplexed protein analysis in fine-needle aspirates. Sci Transl Med 6, 219ra9
24431113   Curated Info

59

Brobeil A, et al. (2014) The known interactome of PTPIP51 in HaCaT cells—inhibition of kinases and receptors. Int J Biochem Cell Biol 46, 19-31
24501773   Curated Info

60

Britton D, et al. (2014) Quantification of pancreatic cancer proteome and phosphorylome: indicates molecular events likely contributing to cancer and activity of drug targets. PLoS One 9, e90948
24670416   Curated Info

61

Vendelbo MH, et al. (2014) Fasting Increases Human Skeletal Muscle Net Phenylalanine Release and This Is Associated with Decreased mTOR Signaling. PLoS One 9, e102031
25020061   Curated Info

62

Rikova K, Hall B (2013) CST Curation Set: 20734, 21161, 30112, 30153, 30154; Year: 2013; Biosample/Treatment: cell line, H1417, DMS79, H128, H209, H524; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

63

Rikova K, Hall B (2013) CST Curation Set: 20735, 21162, 30155, 30156, 30157; Year: 2013; Biosample/Treatment: cell line, DMS53, H526, H69, H82, H446; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

64

Rikova K, Hall B (2013) CST Curation Set: 20736, 21163, 30158, 30159, 30160; Year: 2013; Biosample/Treatment: cell line, A549, H1355, H23, H441, H1792; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

65

Rikova K, Hall B (2013) CST Curation Set: 20737, 21164, 30161, 30162, 30163; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

66

Rikova K, Hall B (2013) CST Curation Set: 20738, 21165, 30164, 30165, 30166; Year: 2013; Biosample/Treatment: cell line, H1650, HCC827, H1975, Calu-3, H2106; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

67

Rikova K, Hall B (2013) CST Curation Set: 20739, 21166, 30167, 30168, 30169; Year: 2013; Biosample/Treatment: cell line, H2342, H2073, Lou-NH91, HCC15, H1703; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

68

Rikova K, Hall B (2013) CST Curation Set: 20740, 21167, 30170, 30171, 30172; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

69

Rikova K, Hall B (2013) CST Curation Set: 20742, 21169, 30176, 30177, 30178; Year: 2013; Biosample/Treatment: cell line, H838, DMS153, H2073, H209, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

70

Giansanti P, et al. (2013) Interrogating cAMP-dependent kinase signaling in Jurkat T cells via a protein kinase A targeted immune-precipitation phosphoproteomics approach. Mol Cell Proteomics 12, 3350-9
23882029   Curated Info

71

Rikova K, Hall B (2013) CST Curation Set: 20741, 21168, 30173, 30174, 30175; Year: 2013; Biosample/Treatment: cell line, H1666, CAL-12T, H2405, HCC44, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

72

Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96
23911959   Curated Info

73

Petit CS, Roczniak-Ferguson A, Ferguson SM (2013) Recruitment of folliculin to lysosomes supports the amino acid-dependent activation of Rag GTPases. J Cell Biol 202, 1107-22
24081491   Curated Info

74

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

75

Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21
23312004   Curated Info

76

Humphrey SJ, et al. (2013) Dynamic Adipocyte Phosphoproteome Reveals that Akt Directly Regulates mTORC2. Cell Metab 17, 1009-20
23684622   Curated Info

77

Rikova K (2013) CST Curation Set: 18531; Year: 2013; Biosample/Treatment: cell line, H3122/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST], LXRXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXXS*/T*) (110B7E) Rabbit mAb Cat#: 9614 Phospho-AMPK Substrate Motif [LXRXX(pS/pT) MultiMab(TM) Rabbit mAb mix Cat#: 5759
Curated Info

78

Rikova K (2013) CST Curation Set: 18529; Year: 2013; Biosample/Treatment: cell line, H2228/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST], LXRXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXXS*/T*) (110B7E) Rabbit mAb Cat#: 9614 Phospho-AMPK Substrate Motif [LXRXX(pS/pT) MultiMab(TM) Rabbit mAb mix Cat#: 5759
Curated Info

79

Tumurkhuu M, et al. (2013) A novel SOS1 mutation in Costello/CFC syndrome affects signaling in both RAS and PI3K pathways. J Recept Signal Transduct Res 33, 124-8
23528009   Curated Info

80

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

81

Chen S, et al. (2013) Tyrosine Kinase BMX Phosphorylates Phosphotyrosine-Primed Motif Mediating the Activation of Multiple Receptor Tyrosine Kinases. Sci Signal 6, ra40
23716717   Curated Info

82

Imami K, et al. (2012) Temporal profiling of lapatinib-suppressed phosphorylation signals in EGFR/HER2 pathways. Mol Cell Proteomics 11, 1741-57
22964224   Curated Info

83

Stokes MP, et al. (2012) PTMScan Direct: Identification and Quantification of Peptides from Critical Signaling Proteins by Immunoaffinity Enrichment Coupled with LC-MS/MS. Mol Cell Proteomics 11, 187-201
22322096   Curated Info

84

Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70
22496350   Curated Info

85

Mulhern D (2012) CST Curation Set: 14049; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q
Curated Info

86

Perl AE, et al. (2012) Single-cell pharmacodynamic monitoring of S6 ribosomal protein phosphorylation in AML blasts during a clinical trial combining the mTOR inhibitor sirolimus and intensive chemotherapy. Clin Cancer Res 18, 1716-25
22167413   Curated Info

87

Mulhern D (2012) CST Curation Set: 13831; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R)Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) PKC Substrate (P-S3-101) Rabbit mAb Cat#: 6967, PTMScan(R) Phospho-PKC Substrate Motif (K/RXS*XK/R) Immunoaffinity Beads Cat#: 6970
Curated Info

88

Singh AM, et al. (2012) Signaling network crosstalk in human pluripotent cells: a Smad2/3-regulated switch that controls the balance between self-renewal and differentiation. Cell Stem Cell 10, 312-26
22385658   Curated Info

89

Mulhern D (2012) CST Curation Set: 13112; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

90

Zhou J (2012) CST Curation Set: 13696; Year: 2012; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

91

Zhou J (2012) CST Curation Set: 13697; Year: 2012; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

92

Mulhern D (2012) CST Curation Set: 13403; Year: 2012; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

93

Gupta M, et al. (2012) Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies. Blood 119, 476-87
22080480   Curated Info

94

Lundby A, et al. (2012) Quantitative maps of protein phosphorylation sites across 14 different rat organs and tissues. Nat Commun 3, 876
22673903   Curated Info

95

Xie J, et al. (2011) cAMP inhibits mammalian target of rapamycin complex-1 and -2 (mTORC1 and 2) by promoting complex dissociation and inhibiting mTOR kinase activity. Cell Signal 23, 1927-35
21763421   Curated Info

96

Warfel NA, Niederst M, Newton AC (2011) Disruption of the interface between the pleckstrin homology (PH) and kinase domains of Akt protein is sufficient for hydrophobic motif site phosphorylation in the absence of mTORC2. J Biol Chem 286, 39122-9
21908613   Curated Info

97

Mulhern D (2011) CST Curation Set: 12742; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

98

Mulhern D (2011) CST Curation Set: 12743; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

99

Mulhern D (2011) CST Curation Set: 12744; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

100

Mulhern D (2011) CST Curation Set: 12745; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

101

Mulhern D (2011) CST Curation Set: 12746; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

102

Mulhern D (2011) CST Curation Set: 12747; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

103

Mulhern D (2011) CST Curation Set: 12748; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

104

Mulhern D (2011) CST Curation Set: 12750; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

105

Yuan J, et al. (2011) PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity. Mol Cancer Ther 10, 2189-99
21750219   Curated Info

106

Mulhern D (2011) CST Curation Set: 12684; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

107

Mulhern D (2011) CST Curation Set: 12685; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

108

Mulhern D (2011) CST Curation Set: 12686; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

109

Mulhern D (2011) CST Curation Set: 12677; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

110

Mulhern D (2011) CST Curation Set: 12678; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

111

Mulhern D (2011) CST Curation Set: 12679; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

112

Mulhern D (2011) CST Curation Set: 12681; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

113

Mulhern D (2011) CST Curation Set: 12682; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

114

Mulhern D (2011) CST Curation Set: 12683; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

115

Roy D, Dittmer DP (2011) Phosphatase and tensin homolog on chromosome 10 is phosphorylated in primary effusion lymphoma and Kaposi's sarcoma. Am J Pathol 179, 2108-19
21819957   Curated Info

116

Mulhern D (2011) CST Curation Set: 12667; Year: 2011; Biosample/Treatment: cell line, HCT116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

117

Mulhern D (2011) CST Curation Set: 12668; Year: 2011; Biosample/Treatment: cell line, HCT116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

118

Bryant KG, et al. (2011) Caveolin-1 overexpression enhances androgen-dependent growth and proliferation in the mouse prostate. Int J Biochem Cell Biol 43, 1318-29
21601007   Curated Info

119

Moritz A (2011) CST Curation Set: 12513; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

120

Guo A (2011) CST Curation Set: 12073; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

121

Zhou J (2011) CST Curation Set: 12026; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY(YXXM) Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Tyr) p85 PI3K Binding Motif Antibody Cat#: 3821
Curated Info

122

Guo A (2011) CST Curation Set: 12034; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpTP
Curated Info

123

Guo A (2011) CST Curation Set: 12035; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpTP
Curated Info

124

Moritz A (2011) CST Curation Set: 12260; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

125

Sarkar S, et al. (2011) Complex inhibitory effects of nitric oxide on autophagy. Mol Cell 43, 19-32
21726807   Curated Info

126

Mazzoletti M, et al. (2011) Combination of PI3K/mTOR inhibitors: antitumor activity and molecular correlates. Cancer Res 71, 4573-84
21602434   Curated Info

127

Guo A (2011) CST Curation Set: 12064; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pTXR Antibodies Used to Purify Peptides prior to LCMS: Phospho-Threonine-X-Arginine Antibody Cat#: 2351, PTMScan(R) Phospho-Thr-X-Arg Motif (T*XR) Immunoaffinity Beads Cat#: 1988
Curated Info

128

Moritz A (2011) CST Curation Set: 12040; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

129

Moritz A (2011) CST Curation Set: 12041; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

130

Moritz A (2011) CST Curation Set: 12042; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

131

Moritz A (2011) CST Curation Set: 12043; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

132

Moritz A (2011) CST Curation Set: 12044; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

133

Moritz A (2011) CST Curation Set: 12045; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

134

Moritz A (2011) CST Curation Set: 12046; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

135

Moritz A (2011) CST Curation Set: 12047; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

136

Moritz A (2011) CST Curation Set: 12048; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

137

Moritz A (2011) CST Curation Set: 12049; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

138

Moritz A (2011) CST Curation Set: 12050; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

139

Moritz A (2011) CST Curation Set: 12051; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

140

Xiang T, et al. (2011) Targeting the Akt/mTOR pathway in Brca1-deficient cancers. Oncogene 30, 2443-50
21242970   Curated Info

141

Moritz A (2011) CST Curation Set: 11933; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

142

Moritz A (2011) CST Curation Set: 11934; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

143

Moritz A (2011) CST Curation Set: 11935; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

144

Moritz A (2011) CST Curation Set: 11936; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

145

Moritz A (2011) CST Curation Set: 11938; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

146

Moritz A (2011) CST Curation Set: 11939; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

147

Moritz A (2011) CST Curation Set: 11940; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

148

Moritz A (2011) CST Curation Set: 11944; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

149

Zhou J (2011) CST Curation Set: 11710; Year: 2011; Biosample/Treatment: cell line, HeLa/UV; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-ATM/ATR Substrate (S*Q) (D23H2/D69H5) Rabbit mAb Cat#: 9607, PTMScan(R) Phospho-ATM/ATR Substrate (S*Q) Immunoaffinity Beads Cat#: 9884
Curated Info

150

Guo A (2011) CST Curation Set: 11634; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) ATM/ATR Substrate Antibody (polyAB) Cat#: 3005, PTMScan(R) Phospho-ATM/ATR Substrate Motif (pS/pTQ) Immunoaffinity Beads Cat#: 1980
Curated Info

151

Guo A (2011) CST Curation Set: 11523; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-ATM/ATR Substrate (S*Q) (D23H2/D69H5) Rabbit mAb Cat#: 9607, PTMScan(R) Phospho-ATM/ATR Substrate (S*Q) Immunoaffinity Beads Cat#: 9884
Curated Info

152

Guo A (2011) CST Curation Set: 11524; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-ATM/ATR Substrate (S*Q) (D23H2/D69H5) Rabbit mAb Cat#: 9607, PTMScan(R) Phospho-ATM/ATR Substrate (S*Q) Immunoaffinity Beads Cat#: 9884
Curated Info

153

Nagashima K, et al. (2011) Genetic and pharmacological inhibition of PDK1 in cancer cells: characterization of a selective allosteric kinase inhibitor. J Biol Chem 286, 6433-48
21118801   Curated Info

154

Guo A (2011) CST Curation Set: 11452; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RRXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-PKA Substrate (RRXS/T) (100G7) Rabbit mAb Cat#: 9624, PTMScan(R) Phospho-PKA Substrate Motif (K/RK/RXS*/T*) Immunoaffinity Beads Cat#: 1984
Curated Info

155

Guo A (2011) CST Curation Set: 11283; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

156

Guo A (2011) CST Curation Set: 11284; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

157

Guo A (2011) CST Curation Set: 11285; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

158

Guo A (2011) CST Curation Set: 11298; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

159

Guo A (2011) CST Curation Set: 11375; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q
Curated Info

160

Guo A (2011) CST Curation Set: 11379; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) ATM/ATR Substrate Antibody (polyAB) Cat#: 3005, PTMScan(R) Phospho-ATM/ATR Substrate Motif (pS/pTQ) Immunoaffinity Beads Cat#: 1980
Curated Info

161

Guo A (2011) CST Curation Set: 11380; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q
Curated Info

162

Possemato A (2011) CST Curation Set: 11327; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

163

Saiki S, et al. (2011) Caffeine induces apoptosis by enhancement of autophagy via PI3K/Akt/mTOR/p70S6K inhibition. Autophagy 7, 176-87
21081844   Curated Info

164

Guo A (2011) CST Curation Set: 11116; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) ATM/ATR Substrate Antibody (polyAB) Cat#: 3005, PTMScan(R) Phospho-ATM/ATR Substrate Motif (pS/pTQ) Immunoaffinity Beads Cat#: 1980
Curated Info

165

Guo A (2011) CST Curation Set: 11115; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) ATM/ATR Substrate Antibody (polyAB) Cat#: 3005, PTMScan(R) Phospho-ATM/ATR Substrate Motif (pS/pTQ) Immunoaffinity Beads Cat#: 1980
Curated Info

166

Rikova K (2011) CST Curation Set: 11008; Year: 2011; Biosample/Treatment: cell line, NCI-H460/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

167

Carriere A, et al. (2011) ERK1/2 phosphorylate Raptor to promote Ras-dependent activation of mTOR complex 1 (mTORC1). J Biol Chem 286, 567-77
21071439   Curated Info

168

Rikova K (2011) CST Curation Set: 10916; Year: 2011; Biosample/Treatment: cell line, NCI-H2170/untreated; Disease: non-small cell squamous cell lung carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

169

Rikova K (2011) CST Curation Set: 10922; Year: 2011; Biosample/Treatment: cell line, NCI-H3122/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

170

Rikova K (2011) CST Curation Set: 10886; Year: 2011; Biosample/Treatment: cell line, NCI-H2342/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

171

Rikova K (2011) CST Curation Set: 10904; Year: 2011; Biosample/Treatment: cell line, NCI-H226/untreated; Disease: non-small cell squamous cell lung carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

172

Rikova K (2011) CST Curation Set: 10918; Year: 2011; Biosample/Treatment: cell line, NCI-H1651/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

173

Rikova K (2011) CST Curation Set: 10890; Year: 2011; Biosample/Treatment: cell line, NCI-H1975/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

174

Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5
21712546   Curated Info

175

Yang S, Xiao X, Meng X, Leslie KK (2011) A mechanism for synergy with combined mTOR and PI3 kinase inhibitors. PLoS One 6, e26343
22039466   Curated Info

176

Possemato A (2010) CST Curation Set: 10959; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

177

Ren H (2010) CST Curation Set: 10740; Year: 2010; Biosample/Treatment: cell line, OVKATE/serum starved; Disease: ovarian cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

178

Wang YT, et al. (2010) An informatics-assisted label-free quantitation strategy that depicts phosphoproteomic profiles in lung cancer cell invasion. J Proteome Res 9, 5582-97
20815410   Curated Info

179

Possemato A (2010) CST Curation Set: 10783; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

180

Possemato A (2010) CST Curation Set: 10790; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

181

Possemato A (2010) CST Curation Set: 10781; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (60D12F4) Rabbit mAb Cat#: 10002
Curated Info

182

Possemato A (2010) CST Curation Set: 10789; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

183

Possemato A (2010) CST Curation Set: 10782; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

184

Possemato A (2010) CST Curation Set: 10787; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

185

Possemato A (2010) CST Curation Set: 10788; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

186

Possemato A (2010) CST Curation Set: 10785; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (81E12B5) Rabbit mAb Cat#: 10003
Curated Info

187

Possemato A (2010) CST Curation Set: 10786; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

188

Possemato A (2010) CST Curation Set: 10792; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

189

Possemato A (2010) CST Curation Set: 10795; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

190

Possemato A (2010) CST Curation Set: 10791; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

191

Possemato A (2010) CST Curation Set: 10780; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (60D12F4) Rabbit mAb Cat#: 10002
Curated Info

192

Possemato A (2010) CST Curation Set: 10794; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

193

Possemato A (2010) CST Curation Set: 10784; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (81E12B5) Rabbit mAb Cat#: 10003
Curated Info

194

Possemato A (2010) CST Curation Set: 10838; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

195

Possemato A (2010) CST Curation Set: 10839; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

196

Possemato A (2010) CST Curation Set: 10777; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

197

Possemato A (2010) CST Curation Set: 10778; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

198

Possemato A (2010) CST Curation Set: 10776; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

199

Possemato A (2010) CST Curation Set: 10718; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RRXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-PKA Substrate (RRXS/T) (100G7) Rabbit mAb Cat#: 9624, PTMScan(R) Phospho-PKA Substrate Motif (K/RK/RXS*/T*) Immunoaffinity Beads Cat#: 1984
Curated Info

200

Possemato A (2010) CST Curation Set: 10716; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

201

Possemato A (2010) CST Curation Set: 10715; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

202

Possemato A (2010) CST Curation Set: 10714; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

203

Possemato A (2010) CST Curation Set: 10734; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (81E12B5) Rabbit mAb Cat#: 10003
Curated Info

204

Possemato A (2010) CST Curation Set: 10726; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

205

Possemato A (2010) CST Curation Set: 10727; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (81E12B5) Rabbit mAb Cat#: 10003
Curated Info

206

Possemato A (2010) CST Curation Set: 10730; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (81E12B5) Rabbit mAb Cat#: 10003
Curated Info

207

Possemato A (2010) CST Curation Set: 10733; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (81E12B5) Rabbit mAb Cat#: 10003
Curated Info

208

Possemato A (2010) CST Curation Set: 10728; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (81E12B5) Rabbit mAb Cat#: 10003
Curated Info

209

Possemato A (2010) CST Curation Set: 10731; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (81E12B5) Rabbit mAb Cat#: 10003
Curated Info

210

Possemato A (2010) CST Curation Set: 10729; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

211

Possemato A (2010) CST Curation Set: 10732; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

212

Moritz A (2010) CST Curation Set: 10614; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

213

Moritz A (2010) CST Curation Set: 10615; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

214

Muaddi H, et al. (2010) Phosphorylation of eIF2α at serine 51 is an important determinant of cell survival and adaptation to glucose deficiency. Mol Biol Cell 21, 3220-31
20660158   Curated Info

215

Possemato A (2010) CST Curation Set: 10530; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

216

Possemato A (2010) CST Curation Set: 10531; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

217

Yang L, et al. (2010) TCR-induced Akt serine 473 phosphorylation is regulated by protein kinase C-alpha. Biochem Biophys Res Commun 400, 16-20
20691662   Curated Info

218

Aksamitiene E, et al. (2010) PI3K/Akt-sensitive MEK-independent compensatory circuit of ERK activation in ER-positive PI3K-mutant T47D breast cancer cells. Cell Signal 22, 1369-78
20471474   Curated Info

219

Xiao K, et al. (2010) Global phosphorylation analysis of beta-arrestin-mediated signaling downstream of a seven transmembrane receptor (7TMR). Proc Natl Acad Sci U S A 107, 15299-304
20686112   Curated Info

220

Possemato A (2010) CST Curation Set: 10291; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

221

Possemato A (2010) CST Curation Set: 10290; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

222

Possemato A (2010) CST Curation Set: 10293; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

223

Possemato A (2010) CST Curation Set: 10288; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

224

Possemato A (2010) CST Curation Set: 10146; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

225

Possemato A (2010) CST Curation Set: 10160; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

226

Possemato A (2010) CST Curation Set: 10161; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

227

Possemato A (2010) CST Curation Set: 10162; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

228

Possemato A (2010) CST Curation Set: 10156; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

229

Possemato A (2010) CST Curation Set: 10149; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

230

Possemato A (2010) CST Curation Set: 10154; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

231

Possemato A (2010) CST Curation Set: 10159; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

232

Possemato A (2010) CST Curation Set: 10152; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

233

Possemato A (2010) CST Curation Set: 10148; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

234

Possemato A (2010) CST Curation Set: 10153; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

235

Possemato A (2010) CST Curation Set: 10151; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

236

Possemato A (2010) CST Curation Set: 10121; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

237

Possemato A (2010) CST Curation Set: 10111; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

238

Possemato A (2010) CST Curation Set: 10120; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

239

Possemato A (2010) CST Curation Set: 10119; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

240

Beausoleil S (2010) CST Curation Set: 10282; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

241

Beausoleil S (2010) CST Curation Set: 10279; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

242

Moritz A (2010) CST Curation Set: 10235; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

243

Moritz A (2010) CST Curation Set: 10237; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

244

Moritz A (2010) CST Curation Set: 10241; Year: 2010; Biosample/Treatment: cell line, NCI-H3255/Iressa; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

245

Moritz A (2010) CST Curation Set: 10239; Year: 2010; Biosample/Treatment: cell line, NCI-H1703/Gleevec; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

246

Moritz A (2010) CST Curation Set: 10242; Year: 2010; Biosample/Treatment: cell line, NCI-H3255/DMSO; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

247

Moritz A (2010) CST Curation Set: 10236; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

248

Moritz A (2010) CST Curation Set: 10231; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

249

Carayol N, et al. (2010) Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells. Proc Natl Acad Sci U S A 107, 12469-74
20616057   Curated Info

250

Possemato A (2010) CST Curation Set: 10127; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

251

Possemato A (2010) CST Curation Set: 10126; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

252

Moritz A (2010) CST Curation Set: 10021; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

253

Moritz A (2010) CST Curation Set: 10020; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

254

Moritz A (2010) CST Curation Set: 9987; Year: 2010; Biosample/Treatment: cell line, NCI-H441/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

255

Guo A (2010) CST Curation Set: 9942; Year: 2010; Biosample/Treatment: cell line, SMS-KCN-A/untreated; Disease: neuroblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

256

Guo A (2010) CST Curation Set: 9946; Year: 2010; Biosample/Treatment: cell line, SH-SY5Y/NGF; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

257

Bennetzen MV, et al. (2010) Site-specific phosphorylation dynamics of the nuclear proteome during the DNA damage response. Mol Cell Proteomics 9, 1314-23
20164059   Curated Info

258

Schreiber TB, et al. (2010) An integrated phosphoproteomics work flow reveals extensive network regulation in early lysophosphatidic acid signaling. Mol Cell Proteomics 9, 1047-62
20071362   Curated Info

259

Possemato A (2010) CST Curation Set: 9750; Year: 2010; Biosample/Treatment: cell line, H1650/Phenformin; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

260

Kilili GK, Kyriakis JM (2010) Mammalian Ste20-like kinase (Mst2) indirectly supports Raf-1/ERK pathway activity via maintenance of protein phosphatase-2A catalytic subunit levels and consequent suppression of inhibitory Raf-1 phosphorylation. J Biol Chem 285, 15076-87
20212043   Curated Info

261

Possemato A (2010) CST Curation Set: 9724; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R)Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) PKC Substrate Antibody Cat#: 2261, PTMScan(R) Phospho-PKC Substrate Motif (K/RXpSXK/R) Immunoaffinity Beads Cat#: 1985
Curated Info

262

Possemato A (2010) CST Curation Set: 9723; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R)
Curated Info

263

Zhou J (2010) CST Curation Set: 9666; Year: 2010; Biosample/Treatment: cell line, NCCIT/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

264

Zhou J (2010) CST Curation Set: 9667; Year: 2010; Biosample/Treatment: cell line, NTERA-2/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

265

Possemato A (2010) CST Curation Set: 9633; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614
Curated Info

266

Possemato A (2010) CST Curation Set: 9617; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

267

Possemato A (2010) CST Curation Set: 9616; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

268

Anastasov N, et al. (2010) C/EBPbeta expression in ALK-positive anaplastic large cell lymphomas is required for cell proliferation and is induced by the STAT3 signaling pathway. Haematologica 95, 760-7
20015877   Curated Info

269

Possemato A (2010) CST Curation Set: 9422; Year: 2010; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

270

Possemato A (2010) CST Curation Set: 9348; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)Xp[ST](I/L/V)
Curated Info

271

Moritz A (2010) CST Curation Set: 9374; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

272

Godlewski J, et al. (2010) MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to metabolic stress in glioma cells. Mol Cell 37, 620-32
20227367   Curated Info

273

Possemato A (2010) CST Curation Set: 9291; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pTXR
Curated Info

274

Moritz A (2010) CST Curation Set: 9279; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO &'||' Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

275

Moritz A (2010) CST Curation Set: 9234; Year: 2010; Biosample/Treatment: cell line, MKN-45/calyculin_A & pervanadate; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

276

Moritz A (2010) CST Curation Set: 9240; Year: 2010; Biosample/Treatment: cell line, NCI-H1703/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

277

Moritz A (2010) CST Curation Set: 9237; Year: 2010; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

278

Moritz A (2010) CST Curation Set: 9243; Year: 2010; Biosample/Treatment: cell line, HeLa/UV; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

279

Moritz A (2010) CST Curation Set: 9245; Year: 2010; Biosample/Treatment: cell line, HeLa/UV; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

280

Moritz A (2010) CST Curation Set: 9239; Year: 2010; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

281

Moritz A (2010) CST Curation Set: 9242; Year: 2010; Biosample/Treatment: cell line, NCI-H1703/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

282

Arvisais E, et al. (2010) Prostaglandin F2alpha represses IGF-I-stimulated IRS1/phosphatidylinositol-3-kinase/AKT signaling in the corpus luteum: role of ERK and P70 ribosomal S6 kinase. Mol Endocrinol 24, 632-43
20160123   Curated Info

283

Rikova K (2010) CST Curation Set: 9208; Year: 2010; Biosample/Treatment: cell line, LAN-6/NGF; Disease: neuroblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

284

Rikova K (2010) CST Curation Set: 9206; Year: 2010; Biosample/Treatment: cell line, SMS-KCN-A/untreated; Disease: neuroblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

285

Rikova K (2010) CST Curation Set: 9209; Year: 2010; Biosample/Treatment: cell line, SH-SY5Y/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

286

Rikova K (2010) CST Curation Set: 9210; Year: 2010; Biosample/Treatment: cell line, SH-SY5Y/NGF; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

287

Possemato A (2010) CST Curation Set: 8992; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

288

Treins C, et al. (2010) Rictor is a novel target of p70 S6 kinase-1. Oncogene 29, 1003-16
19935711   Curated Info

289

Banerjee S, et al. (2010) The neurofibromatosis type 1 tumor suppressor controls cell growth by regulating signal transducer and activator of transcription-3 activity in vitro and in vivo. Cancer Res 70, 1356-66
20124472   Curated Info

290

Possemato A (2010) CST Curation Set: 9074; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y)XpSAntibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) Arg-X-Tyr/Phe-X-pSer Motif Antibody Cat#: 2981
Curated Info

291

Possemato A (2010) CST Curation Set: 9072; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y)XpS
Curated Info

292

Possemato A (2010) CST Curation Set: 9073; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y)XpS
Curated Info

293

Possemato A (2010) CST Curation Set: 9071; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y)XpS
Curated Info

294

Ham BM, et al. (2010) Novel Ser/Thr protein phosphatase 5 (PP5) regulated targets during DNA damage identified by proteomics analysis. J Proteome Res 9, 945-53
20039704   Curated Info

295

Possemato A (2010) CST Curation Set: 9055; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

296

Possemato A (2010) CST Curation Set: 9054; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

297

Possemato A (2010) CST Curation Set: 9053; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

298

Moritz A (2010) CST Curation Set: 9065; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

299

Moritz A (2010) CST Curation Set: 9064; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

300

Rikova K (2010) CST Curation Set: 9019; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

301

Possemato A (2010) CST Curation Set: 9038; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

302

Yamnik RL, Holz MK (2010) mTOR/S6K1 and MAPK/RSK signaling pathways coordinately regulate estrogen receptor alpha serine 167 phosphorylation. FEBS Lett 584, 124-8
19925796   Curated Info

303

Chresta CM, et al. (2010) AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res 70, 288-98
20028854   Curated Info

304

Yoshizawa A, et al. (2010) Overexpression of phospho-eIF4E is associated with survival through AKT pathway in non-small cell lung cancer. Clin Cancer Res 16, 240-8
20008839   Curated Info

305

Moritz A, et al. (2010) Akt-RSK-S6 Kinase Signaling Networks Activated by Oncogenic Receptor Tyrosine Kinases. Sci Signal 3, ra64
20736484   Curated Info

306

Dere R, Wilson PD, Sandford RN, Walker CL (2010) Carboxy terminal tail of polycystin-1 regulates localization of TSC2 to repress mTOR. PLoS One 5, e9239
20169078   Curated Info

307

Tucker M (2009) CST Curation Set: 8741; Year: 2009; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

308

Moritz A (2009) CST Curation Set: 8723; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

309

Moritz A (2009) CST Curation Set: 8725; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

310

Moritz A (2009) CST Curation Set: 8726; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

311

Moritz A (2009) CST Curation Set: 8724; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

312

Possemato A (2009) CST Curation Set: 8598; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

313

Possemato A (2009) CST Curation Set: 8594; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

314

Possemato A (2009) CST Curation Set: 8595; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

315

Possemato A (2009) CST Curation Set: 8596; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

316

Possemato A (2009) CST Curation Set: 8599; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

317

Possemato A (2009) CST Curation Set: 8588; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

318

Possemato A (2009) CST Curation Set: 8589; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

319

Possemato A (2009) CST Curation Set: 8590; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

320

Possemato A (2009) CST Curation Set: 8591; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

321

Pan C, Olsen JV, Daub H, Mann M (2009) Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics 8, 2796-808
19651622   Curated Info

322

Tucker M (2009) CST Curation Set: 8371; Year: 2009; Biosample/Treatment: tissue, skin/untreated; Disease: melanoma skin cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

323

Tucker M (2009) CST Curation Set: 8375; Year: 2009; Biosample/Treatment: tissue, skin/untreated; Disease: melanoma skin cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

324

Tucker M (2009) CST Curation Set: 8367; Year: 2009; Biosample/Treatment: tissue, skin/untreated; Disease: melanoma skin cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

325

Possemato A (2009) CST Curation Set: 8361; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

326

Possemato A (2009) CST Curation Set: 8050; Year: 2009; Biosample/Treatment: cell line, NCI-H1650/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

327

Moritz A (2009) CST Curation Set: 7938; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

328

Moritz A (2009) CST Curation Set: 7937; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

329

Moritz A (2009) CST Curation Set: 7933; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

330

Moritz A (2009) CST Curation Set: 7932; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

331